ℹ️
🇬🇧
Search
Search for publications relevant for "Bruton tyrosine kinase"
Bruton tyrosine kinase
Publication
Class
Person
Publication
Programmes
publication
Bruton's tyrosine kinase inhibitors and their current status in the treatment of chronic lymphocytic leukemia
2023 |
First Faculty of Medicine
publication
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
2020 |
Faculty of Pharmacy in Hradec Králové
publication
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux
2022 |
Faculty of Pharmacy in Hradec Králové
publication
Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma
2020 |
First Faculty of Medicine
publication
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
2022 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové
publication
Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia
+1
2008 |
Second Faculty of Medicine
publication
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic
2023 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
publication
Contiguous x-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes
2007 |
Second Faculty of Medicine
publication
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
2016 |
First Faculty of Medicine
publication
Research Report University Hospital for clinical evaluation of PCI-32765MCL3002
Publication without faculty affiliation
publication
Report of University Hospital Hradec Králové to the clinical trial protocol No: PCYC-1115-CA
Publication without faculty affiliation
publication
Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PCYC-1130-CA
Publication without faculty affiliation
publication
Use of ibrutinib as "bridging" for allogeneic hematopoietic stem cell transplantation from haploidentic donor and subsequent therapy of residual disease after transplantation in a patient with highly adverse mantle cell lymphoma
2019 |
First Faculty of Medicine
publication
Dendritic cells in immunopathology
Publication without faculty affiliation
publication
Severe secondary immune thrombocytopenia in a patient with chronic lymphocytic leukemia
2022 |
Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
publication
Fixed duration therapy in patients with chronic lymphocytic leukemia
2023 |
Publication without faculty affiliation
publication
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
2021 |
Faculty of Medicine in Hradec Králové
publication
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy
2020 |
Second Faculty of Medicine
publication
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
2021 |
Faculty of Medicine in Hradec Králové
publication
Small Molecules in the Treatment of Chronic Lymphocytic Leukemia in 2015 and in the Near Future
2015 |
First Faculty of Medicine
publication
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
2017 |
First Faculty of Medicine
publication
COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group
2023 |
Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
publication
Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)
2023 |
First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
publication
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
2020 |
First Faculty of Medicine
publication
Mantle cell lymphoma: insights into therapeutic targets at the preclinical level
2020 |
First Faculty of Medicine
publication
Detailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma Cells
2015 |
First Faculty of Medicine
publication
Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions
2016 |
Faculty of Medicine in Hradec Králové
publication
Modern approach to the treatment of chronic lymphocytic leukemia
2023 |
Faculty of Medicine in Hradec Králové
publication
The terapeutic Options for ""Slow- go"" Patients with Chronic Lymphocytic Leukemia
2015 |
Faculty of Medicine in Hradec Králové